NCT02619253View on ClinicalTrials.gov

Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 23, 2016

Primary Completion Date

March 28, 2023

Study Completion Date

March 28, 2023

Conditions
Renal Cell CarcinomaUrinary Bladder Neoplasms
Interventions
DRUG

Pembrolizumab

DRUG

Vorinostat

Trial Locations (4)

21205

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

46202

Indiana University Hospital, Indianapolis

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
lead

Nabil Adra

OTHER

NCT02619253 - Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma | Biotech Hunter | Biotech Hunter